Principal Investigators

    Henrik Zetterberg


    University of Gothenburg

    Contact information of lead PI



    Title of project or programme

    Pathways to Alzheimer´s disease

    Source of funding information

    Swedish Research Council

    Total sum awarded (Euro)

    € 707,291

    Start date of award


    Total duration of award in years



    Research Abstract

    Alzheimer´s disease (AD) is characterised by deposits of amyloid beta (Abeta) in senile plaques in the brain. One of the major unresolved questions in AD research is why Abeta, which is produced by all human beings, turns toxic and starts damaging nerve cells only in some individuals while others appear protected. We hypothesise that Abeta starts to accumulate in the brain of certain individuals due to defective clearance of the peptide. This clearance failure may be linked to defective enzymatic degradation of Abeta or impaired binding of Abeta monomers to carrier proteins. Once aggregated, Abeta may acquire chemical modifications during incubation in the brain over years, which makes it more prone to form structures that over-activate the immune system, resulting in frank neurotoxicity. We also hypothesise that certain individuals are more or less sensitive to Abeta toxicity. Using patient materials and cell, zebrafish and hippocampal slice models, we will address these hypotheses with special emphasis on Abeta-interacting proteins and peptides, Abeta-degrading proteases and the role of the microglial defence system as a potential mediator of Abeta toxicity. The project may give important clues on cause-and-effect relationships in the early pathogenic process of AD and should result in novel targets for treatment and new biomarkers for the disease.

    Further information available at:

Types: Investments < €500k
Member States: Sweden
Diseases: N/A
Years: 2016
Database Categories: N/A
Database Tags: N/A

Export as PDF